Prenetics reports Q1 EPS (80c) vs ($1.31) last year

Reports Q1 revenue $17.3M vs $10.49M last year. Danny Yeung, Chief Executive Officer and Co-Founder, remarked: “The first quarter of 2025 marked an exceptionally strong start for Prenetics (PRE), with financial performance that significantly surpassed expectations and strategic advancements that position us for accelerated growth. We are thrilled to report robust momentum, with revenue increasing by an impressive 336.5% year-over-year to $14.4 million. Our strategic realignment towards the global consumer healthcare market is gaining tremendous traction. This strong start to the year is reflected in our revised full year outlook for the year in which we are raising our revenue expectations from $73 – $85 million to $80 – $100 million, reflecting the accelerating momentum across our business units. Additionally, we expect IM8’s second quarter revenue to reach approximately $8.5 million, representing a 50% quarter-over-quarter increase.”